Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Brian I. Rini, Elizabeth R. Plimack, V.P. Stus, +24

New England Journal of Medicine

Rituximab-Dependent Cytotoxicity by Natural Killer Cells

Sébastien Dall’Ozzo, Sophie Tartas, Gilles Paintaud, +5

Cancer Research

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park, +226

The Lancet Oncology

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled, +342

The Lancet

Breast OncologyOncologyEarly Breast CancerRandomised TrialBreast Cancer +4

Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs

Florence Ranchon, Gilles Salles, Hans-Martin Späth, +12

BMC Cancer

Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma

Bernard Lemieux, Sophie Tartas, Catherine Traullé, +7

Bone Marrow Transplantation

Lymphoid NeoplasiaTransplantationAggressive Non-hodgkinMalignant Blood DisorderImmunology +6

Maintenance Therapy with a Monthly Injection of Alemtuzumab Prolongs Response Duration in Patients with Refractory B-cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (B-CLL/SLL)

Catherine Thiéblemont, Fadhela Bouafia, E. Hornez, +8

Leukemia & lymphoma/Leukemia and lymphoma

Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial

Brian I. Rini, Michael B. Atkins, Elizabeth R. Plimack, +16

European Urology Oncology

UrologyHepatologyMedicineKeynote-426 TrialHepatotoxicity +5

Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial

Marc‐Oliver Grimm, Emilio Esteban, Philippe Barthélémy, +39

The Lancet Oncology

UrologyImmunotherapeutic BoostGenitourinary CancerMedicineImmunology +6

An ambispective observational study in the safety and efficacy of abiraterone acetate in the French temporary authorizations for use (ATU): Predictive parameters of response.

D. Azria, Christophe Massard, Diégo Tosi, +16

Journal of Clinical Oncology

Ambispective Observational StudyMedian DurationTemporary AuthorizationsPharmacotherapyLogistic Analysis +17